These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 18331436

  • 1. Omega-3 fatty acid supplementation and total homocysteine levels in end-stage renal disease patients.
    Beavers KM, Beavers DP, Bowden RG, Wilson RL, Gentile M.
    Nephrology (Carlton); 2008 Jun; 13(4):284-8. PubMed ID: 18331436
    [Abstract] [Full Text] [Related]

  • 2. Effect of over-the-counter fish-oil administration on plasma Lp(a) levels in an end-stage renal disease population.
    Beavers KM, Beavers DP, Bowden RG, Wilson RL, Gentile M.
    J Ren Nutr; 2009 Nov; 19(6):443-9. PubMed ID: 19748798
    [Abstract] [Full Text] [Related]

  • 3. The content of docosahexaenoic acid in serum phospholipid is inversely correlated with plasma homocysteine levels in patients with end-stage renal disease.
    Rasmussen LE, Svensson M, Jørgensen KA, Schmidt EB, Christensen JH.
    Nutr Res; 2010 Aug; 30(8):535-40. PubMed ID: 20851307
    [Abstract] [Full Text] [Related]

  • 4. Fish oil supplementation lowers C-reactive protein levels independent of triglyceride reduction in patients with end-stage renal disease.
    Bowden RG, Wilson RL, Deike E, Gentile M.
    Nutr Clin Pract; 2009 Aug; 24(4):508-12. PubMed ID: 19461006
    [Abstract] [Full Text] [Related]

  • 5. Intravenous administration of vitamin B12 in the treatment of hyperhomocysteinemia associated with end-stage renal disease.
    Vrentzos GE, Papadakis JA, Vardakis KE, Maliaraki N, Stilianou K, Arvanitis A, Sratigis S, Alivanis P, Margioris AN, Ganotakis ES.
    J Nephrol; 2003 Aug; 16(4):535-9. PubMed ID: 14696755
    [Abstract] [Full Text] [Related]

  • 6. Vitamin B12 decreases, but does not normalize, homocysteine and methylmalonic acid in end-stage renal disease: a link with glycine metabolism and possible explanation of hyperhomocysteinemia in end-stage renal disease.
    Hyndman ME, Manns BJ, Snyder FF, Bridge PJ, Scott-Douglas NW, Fung E, Parsons HG.
    Metabolism; 2003 Feb; 52(2):168-72. PubMed ID: 12601627
    [Abstract] [Full Text] [Related]

  • 7. Effects of omega-3 fatty acid supplementation on lipid levels in endstage renal disease patients.
    Bowden RG, Jitomir J, Wilson RL, Gentile M.
    J Ren Nutr; 2009 Jul; 19(4):259-66. PubMed ID: 19539180
    [Abstract] [Full Text] [Related]

  • 8. Controlled trials of very high dose folic acid, vitamins B12 and B6, intravenous folinic acid and serine for treatment of hyperhomocysteinemia in ESRD.
    Gonin JM, Nguyen H, Gonin R, Sarna A, Michels A, Masri-Imad F, Bommareddy G, Chassaing C, Wainer I, Loya A, Cary D, Barker LF, Assefi A, Greenspan R, Mahoney D, Wilcox CS.
    J Nephrol; 2003 Jul; 16(4):522-34. PubMed ID: 14696754
    [Abstract] [Full Text] [Related]

  • 9. Elevated homocysteine levels in patients with end-stage renal disease.
    Nair AP, Nemirovsky D, Kim M, Geer EB, Farkouh ME, Winston J, Halperin JL, Robbins MJ.
    Mt Sinai J Med; 2005 Nov; 72(6):365-73. PubMed ID: 16358160
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of folate and vitamin B12 in lowering homocysteine concentrations in hemodialysis patients.
    Azadibakhsh N, Hosseini RS, Atabak S, Nateghiyan N, Golestan B, Rad AH.
    Saudi J Kidney Dis Transpl; 2009 Sep; 20(5):779-88. PubMed ID: 19736473
    [Abstract] [Full Text] [Related]

  • 11. Homocysteine and vascular access thrombosis in end-stage renal disease patients: a retrospective study.
    Bowden RG, Wyatt FB, Wilson R.
    J Nephrol; 2002 Sep; 15(6):666-70. PubMed ID: 12495281
    [Abstract] [Full Text] [Related]

  • 12. Dimercaptosuccinic acid for the treatment of hyperhomocysteinemia in hemodialysis patients: a placebo-controlled, double-blind, randomized trial.
    House AA, Eliasziw M, Urquhart BL, Freeman DJ, Spence JD.
    Am J Kidney Dis; 2004 Oct; 44(4):689-94. PubMed ID: 15384020
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [The treatment of hyperhomocysteinemia in patients on dialysis: folic acid or the high-flow polysulphonic membrane?].
    Lovcić V, Kes P, Zeljko R, Kusec V.
    Acta Med Croatica; 2006 Jun; 60(3):201-8. PubMed ID: 16933832
    [Abstract] [Full Text] [Related]

  • 17. [Effect of folic acid supplementation on total homocysteine levels in hemodialysis patients].
    Armada E, Pérez Melón C, Otero A, Gayoso P, Rodríguez M, Esteban Morcillo J.
    Nefrologia; 2001 Jun; 21(2):167-73. PubMed ID: 11464650
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The effect of n-3 fatty acids on lipids and lipoproteins in patients treated with chronic haemodialysis: a randomized placebo-controlled intervention study.
    Svensson M, Schmidt EB, Jørgensen KA, Christensen JH.
    Nephrol Dial Transplant; 2008 Sep; 23(9):2918-24. PubMed ID: 18436564
    [Abstract] [Full Text] [Related]

  • 20. Comparison of fatty acid contents of erythrocyte membrane in hemodialysis and peritoneal dialysis patients.
    An WS, Kim SE, Kim KH, Lee S, Park Y, Kim HJ, Vaziri ND.
    J Ren Nutr; 2009 Jul; 19(4):267-74. PubMed ID: 19539181
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.